

Michele Rubini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7874386/publications.pdf>

Version: 2024-02-01

74
papers

4,854
citations

159585

30
h-index

118850

62
g-index

76
all docs

76
docs citations

76
times ranked

4611
citing authors

#	ARTICLE	IF	CITATIONS
1	Prioritization of putatively detrimental variants in euploid miscarriages. <i>Scientific Reports</i> , 2022, 12, 1997.	3.3	3
2	MTHFR promoter methylation might mitigate the effect of smoking at the level of LINE-1 in cleft lip tissues: A preliminary study. <i>Birth Defects Research</i> , 2021, 113, 1463-1469.	1.5	0
3	Rescuing effect of folates on methotrexate cytotoxicity in human trophoblast cells. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1
4	Ultrastructural analysis of collagen fibril diameter distribution in cleft lip. <i>Oral Diseases</i> , 2019, 25, 206-214.	3.0	4
5	LINE-1 methylation in cleft lip tissues: Influence of infant MTHFR c.677C>T genotype. <i>Oral Diseases</i> , 2019, 25, 1668-1671.	3.0	7
6	Nonsyndromic cleft palate: An association study at GWAS candidate loci in a multiethnic sample. <i>Birth Defects Research</i> , 2018, 110, 871-882.	1.5	11
7	Muscle fiber diameter assessment in cleft lip using image processing. <i>Oral Diseases</i> , 2018, 24, 476-481.	3.0	4
8	Evaluating LINE-1 methylation in cleft lip tissues and its association with early pregnancy exposures. <i>Epigenomics</i> , 2018, 10, 105-113.	2.1	14
9	Association between a common missense variant in <i>LOXL3</i> gene and the risk of nonsyndromic cleft palate. <i>Congenital Anomalies (discontinued)</i> , 2018, 58, 136-140.	0.6	7
10	Genetic Interactions in Nonsyndromic Orofacial Clefts in Europe—EUROCRAN Study. <i>Cleft Palate-Craniofacial Journal</i> , 2017, 54, 623-630.	0.9	18
11	THU0022—Replication analysis of gene-gene interaction between HLA-DQA2 and HLA-DQB2 variants in Italian rheumatoid arthritis patients. , 2017, , .		0
12	Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 1777-1786.	6.4	58
13	Meta-analysis Reveals Genome-Wide Significance at 15q13 for Nonsyndromic Clefting of Both the Lip and the Palate, and Functional Analyses Implicate GREM1 As a Plausible Causative Gene. <i>PLoS Genetics</i> , 2016, 12, e1005914.	3.5	66
14	Tooth agenesis and orofacial clefting: genetic brothers in arms?. <i>Human Genetics</i> , 2016, 135, 1299-1327.	3.8	46
15	PULSE, a phase 2 study of mFOLFOX6-panitumumab (P) with biomarker stratification as first-line chemotherapy (CT), in patients (pts) with KRAS (exon 2) metastatic colorectal cancer (mCRC). A GEMCAD 09-03 study. <i>Annals of Oncology</i> , 2016, 27, vi164.	1.2	0
16	Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. <i>Clinical Sarcoma Research</i> , 2016, 6, 10.	2.3	1
17	Systematic analysis of copy number variants of a large cohort of orofacial cleft patients identifies candidate genes for orofacial clefts. <i>Human Genetics</i> , 2016, 135, 41-59.	3.8	42
18	Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)]. <i>Journal of Clinical Oncology</i> , 2016, 34, 583-583.	1.6	0

#	ARTICLE	IF	CITATIONS
19	AB0014...Gender-Dependent Association Between HLA-G 14B Insertion/Deletion Polymorphism and Rheumatoid Arthritis in Italian Patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 895.3-896.	0.9	0
20	Generation and Characterization of a Transgenic Mouse Carrying a Functional Human β -Globin Gene with the IVSI-6 Thalassemia Mutation. <i>BioMed Research International</i> , 2015, 2015, 1-20.	1.9	2
21	A new method of detecting changes in corneal health in response to toxic insults. <i>Micron</i> , 2015, 78, 45-53.	2.2	2
22	Prognosis of Phosphorylated-Insulin Growth Factor Receptor (P-Igf-1R) and Metalloproteinase-3 (Mmp3) Expression in Advanced Gastrointestinal Stromal Tumors (Gist) Patients Treated with Imatinib. a Geis Study. <i>Annals of Oncology</i> , 2014, 25, iv76.	1.2	0
23	Genome-wide analysis of parent-of-origin effects in non-syndromic orofacial clefts. <i>European Journal of Human Genetics</i> , 2014, 22, 822-830.	2.8	12
24	Strong Association of Variants around <i>FOXE1</i> and Orofacial Clefting. <i>Journal of Dental Research</i> , 2014, 93, 376-381.	5.2	51
25	PS-362...Epidemiology Of Orofacial Clefts In Emilia Romagna And Tuscany Regions. <i>Archives of Disease in Childhood</i> , 2014, 99, A242.2-A242.	1.9	0
26	Confirming genes influencing risk to cleft lip with/without cleft palate in a case-parent trio study. <i>Human Genetics</i> , 2013, 132, 771-781.	3.8	134
27	Mechanism of Inflammation in Age-Related Macular Degeneration: An Up-to-Date on Genetic Landmarks. <i>Mediators of Inflammation</i> , 2013, 2013, 1-13.	3.0	52
28	Analysis of susceptibility loci for nonsyndromic orofacial clefting in a European trio sample. <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 2545-2549.	1.2	21
29	Genome-wide meta-analyses of nonsyndromic cleft lip with or without cleft palate identify six new risk loci. <i>Nature Genetics</i> , 2012, 44, 968-971.	21.4	311
30	Incidence and patterns of phospho insulin growth factor receptor-1 (pIGF-1R) and matrilysin (MMP7) expression in metastatic colorectal cancer (mCRC), and correlation with KRAS status: A prospective evaluation in the PULSE trial-A GEMCAD study.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14041-e14041.	1.6	0
31	FAF1, a Gene that Is Disrupted in Cleft Palate and Has Conserved Function in Zebrafish. <i>American Journal of Human Genetics</i> , 2011, 88, 150-161.	6.2	57
32	Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: A GEMCAD study. <i>Cancer Biology and Therapy</i> , 2011, 11, 177-183.	3.4	8
33	PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor) Tj ETQq1 1 0.784314 rgBT /Overlock previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6-A GEMCAD study.. <i>Journal of Clinical Oncology</i> , 2011, 29, TPS164-TPS164.	1.6	0
34	Genome-wide association study identifies two susceptibility loci for nonsyndromic cleft lip with or without cleft palate. <i>Nature Genetics</i> , 2010, 42, 24-26.	21.4	379
35	Key susceptibility locus for nonsyndromic cleft lip with or without cleft palate on chromosome 8q24. <i>Nature Genetics</i> , 2009, 41, 473-477.	21.4	415
36	Exclusion of COL2A1 and VDR as Developmental Dysplasia of the Hip Genes. <i>Clinical Orthopaedics and Related Research</i> , 2008, 466, 878-883.	1.5	38

#	ARTICLE	IF	CITATIONS
37	Disruption of an AP-2 binding site in an IRF6 enhancer is associated with cleft lip. <i>Nature Genetics</i> , 2008, 40, 1341-1347.	21.4	382
38	HLA genotype and HLA expression in systemic lupus erythematosus: HLA as a putative susceptibility gene in systemic lupus erythematosus. <i>Tissue Antigens</i> , 2008, 71, 520-529.	1.0	118
39	P2X ₇ gene polymorphisms do not appear to be a susceptibility gene locus in sporadic cases of systemic lupus erythematosus. <i>Tissue Antigens</i> , 2008, 72, 487-490.	1.0	14
40	Colorectal cancer screening: Results of a 5-year program in asymptomatic subjects at increased risk. <i>Digestive and Liver Disease</i> , 2007, 39, 33-39.	0.9	23
41	HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 615-623.	1.5	73
42	Cystathionine beta-synthase c.844ins68 gene variant and non-syndromic cleft lip and palate. <i>American Journal of Medical Genetics, Part A</i> , 2005, 136A, 368-372.	1.2	31
43	Development of strategies for the use of anti-growth factor treatments. <i>Endocrine-Related Cancer</i> , 2005, 12, S173-S182.	3.1	33
44	Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. <i>Endocrine-Related Cancer</i> , 2005, 12, S99-S111.	3.1	185
45	Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2004, 11, 793-814.	3.1	271
46	Epidemiology of Cleft Palate in Europe: Implications for Genetic Research. <i>Cleft Palate-Craniofacial Journal</i> , 2004, 41, 244-249.	0.9	88
47	Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. <i>Oncogene</i> , 2001, 20, 3857-3868.	5.9	82
48	Screening colonoscopy in asymptomatic increased-risk subjects. <i>European Journal of Cancer Prevention</i> , 2001, 10, 175-176.	1.3	0
49	Characterization of an Antibody That Can Detect an Activated IGF-I Receptor in Human Cancers. <i>Experimental Cell Research</i> , 1999, 251, 22-32.	2.6	20
50	Identification of Signalling Components in Tyrosine Kinase Cascades Using Phosphopeptide Affinity Chromatography. <i>Biochemical and Biophysical Research Communications</i> , 1997, 234, 748-753.	2.1	5
51	The IGF-I Receptor in Mitogenesis and Transformation of Mouse Embryo Cells: Role of Receptor Number. <i>Experimental Cell Research</i> , 1997, 230, 284-292.	2.6	116
52	The IGF-I receptor in cell growth, transformation and apoptosis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1997, 1332, F105-F126.	7.4	215
53	PROTOANEMONIN-INDUCED CYTOTOXIC EFFECTS IN EUGLENA GRACILIS. <i>Cell Biology International</i> , 1997, 21, 397-404.	3.0	5
54	Protective effect of the insulin-like growth factor I receptor on apoptosis induced by okadaic acid. <i>Cancer Research</i> , 1997, 57, 3264-71.	0.9	51

#	ARTICLE	IF	CITATIONS
55	An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. <i>Blood</i> , 1996, 87, 682-690.	1.4	174
56	RAPD analysis of systematic relationships among the Cervidae. <i>Heredity</i> , 1996, 76, 215-221.	2.6	36
57	Heteromorphic Variant 18ph+ Analyzed by Sequential CBG and Fluorescence in situ Hybridization. <i>Human Heredity</i> , 1994, 44, 295-297.	0.8	8
58	The role of the IGFâ€ receptor in the growth and transformation of mammalian cells. <i>Cell Proliferation</i> , 1994, 27, 63-71.	5.3	152
59	Platelet-Derived Growth Factor Increases the Activity of the Promoter of the Insulin-like Growth Factor-1 (IGF-1) Receptor Gene. <i>Experimental Cell Research</i> , 1994, 211, 374-379.	2.6	96
60	Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. <i>Cancer Research</i> , 1994, 54, 2218-22.	0.9	244
61	Identification of a novel protein kinase C inhibitor in microsomes from phytohaemagglutinin activated human peripheral blood mononuclear cells. <i>FEBS Letters</i> , 1993, 329, 324-328.	2.8	4
62	Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 11217-11221.	7.1	507
63	Cytological Characterization of a Giant Strain of <i>Euglena gracilis</i> Obtained from Dark-starved Cultures. <i>Botanica Acta</i> , 1993, 106, 473-479.	1.6	3
64	Anchored anti-HLA class I monoclonal antibody fails to induce inhibition of PHA- activated lymphocytes proliferation. <i>Biochemical and Biophysical Research Communications</i> , 1992, 188, 278-285.	2.1	0
65	Altered proliferative kinetics in PHA-activated human T-lymphocytes treated with the anti-HLA class I monoclonal antibody 01.65. <i>Cell Proliferation</i> , 1992, 25, 405-414.	5.3	3
66	High-resolution G-banded karyotype of <i>Cervus elaphus corsicanus</i> , Erxleben. <i>Caryologia</i> , 1991, 44, 375-381.	0.3	1
67	Chromosomal evolution in cervidae. <i>BioSystems</i> , 1990, 24, 157-174.	2.0	101
68	An anti-HLA class I monoclonal antibody alters the progression in the cell cycle of phytohemagglutinin-activated human T lymphocytes. <i>Experimental Cell Research</i> , 1990, 187, 11-15.	2.6	7
69	Standard G-banded karyotype, constitutive heterochromatin and nucleolus organizer regions in the roe deer (<i>Capreolus capreolus</i> L.). <i>Genetica</i> , 1988, 77, 143-148.	1.1	8
70	Depletion of protein kinase C induced by an anti HLA class I monoclonal antibody in phytohemagglutinin activated human T cells. <i>Biochemical and Biophysical Research Communications</i> , 1988, 152, 951-956.	2.1	7
71	Anti HLA class I monoclonal antibody effect on PKC kinetics in PHA activated human peripheral blood mononuclear and E4 cells. <i>Biochemical and Biophysical Research Communications</i> , 1988, 156, 46-53.	2.1	7
72	Cytogenetic studies on <i>Cervus elaphus</i> . <i>Genetica</i> , 1987, 74, 119-124.	1.1	1

#	ARTICLE	IF	CITATIONS
73	Cytogenetic Studies on Cervus Elaphus L. Constitutive Heterochromatin and Nucleolus Organizer Regions. Caryologia, 1984, 37, 439-443.	0.3	13
74	Rescuing effect of folates on methotrexate cytotoxicity in human trophoblast cells. Clinical and Experimental Rheumatology, 0, , .	0.8	3